Eltrombopag
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Eltrombopag: From Thrombocytopenia (ITP) to HIV Infectious Disease
One-Sentence Summary
Eltrombopag is a thrombopoietin (TPO) receptor agonist originally used to raise platelet counts in chronic immune thrombocytopenia (ITP) and related thrombocytopenic conditions. The TxGNN model predicts it may be effective for HIV Infectious Disease, with 5 clinical trials and 10 publications currently associated with this pairing — though as detailed below, most of this evidence addresses managing thrombocytopenia in HIV patients rather than treating HIV itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Thrombocytopenia (ITP) — no formal EU label text available (regulatory data gap, see DG001) |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.26% |
| Evidence Level | L4 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
A structured DrugBank MOA record is not yet available for this drug (data gap DG002). However, the evidence pack’s own trial and literature annotations consistently describe eltrombopag as a TPO receptor (MPL) agonist used clinically to stimulate platelet production in ITP and other thrombocytopenic conditions. It has no known intrinsic antiviral pharmacophore.
The apparent link to HIV is largely indirect: HIV infection is a well-recognized cause of secondary immune thrombocytopenia and, less commonly, aplastic anemia, so eltrombopag has been used off-label to manage these hematologic complications in HIV-positive patients — not to treat the underlying viral infection. This distinction matters, because it suggests TxGNN’s association may partly reflect comorbidity co-occurrence in the knowledge graph rather than a direct therapeutic mechanism against HIV.
One notable exception is an in vitro high-throughput screening study (PMID 32977702) that identified eltrombopag as a candidate modulator of HIV-1 proviral transcription — a preliminary mechanistic hypothesis that has not been validated in cellular models beyond the screen or in any clinical study. Taken together, the mechanistic rationale supports eltrombopag’s role in supportive care for HIV-associated cytopenias with a speculative, unconfirmed direct antiviral hypothesis layered on top.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00996216 | Phase 3 | Completed | 27 | Open-label rollover safety/tolerability study in HCV-related thrombocytopenia (ITP), enabling antiviral therapy initiation — not HIV-specific (relevance grade C). |
| NCT00678587 | Phase 3 | Terminated | 292 | Double-blind, placebo-controlled trial reducing platelet transfusion need in chronic liver disease patients undergoing invasive procedures — terminated early, no direct HIV relevance (grade C). |
| NCT00529568 | Phase 3 | Completed | 759 | Placebo-controlled ITP pivotal trial in HCV thrombocytopenia to enable antiviral therapy (peginterferon alfa-2b + ribavirin) — HIV not a study condition (grade C). |
| NCT01636778 | Phase 2 | Completed | 45 | Open-label study raising platelet counts in HCV-related thrombocytopenia with compensated cirrhosis — not HIV-focused (grade C). |
| NCT00516321 | Phase 3 | Completed | 687 | Placebo-controlled ITP pivotal trial in HCV thrombocytopenia (peginterferon alfa-2a + ribavirin) — HIV not a study condition (grade C). |
Note: None of the five registered trials were designed to test efficacy against HIV infection; all target thrombocytopenia in hepatitis C / liver disease populations and are only indirectly relevant via shared TPO-agonist pharmacology.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 19932434 | 2009 | Review | Hematology/Oncology Clinics of North America | Reviews infectious causes (HCV, HIV, H. pylori) of chronic immune thrombocytopenia; treating the underlying infection often improves platelet counts. |
| 19245929 | 2009 | Review | Seminars in Hematology | Reviews therapeutic strategies for infection-related (including HIV) immune thrombocytopenia. |
| 24816314 | 2014 | Review | Internal Medicine Journal | Reviews TPO-receptor agonist use in ITP of less than 6 months’ duration. |
| 22185370 | 2012 | Cohort (registry) | Platelets | Danish registry of off-label TPO-receptor agonist use in refractory ITP, including secondary cases. |
| 25504472 | 2015 | Case series | Journal of the International Association of Providers of AIDS Care | Case series on TPO-receptor agonists (eltrombopag, romiplostim) as salvage therapy for refractory HIV-associated ITP after HAART optimization. |
| 22992580 | 2012 | Case report | AIDS | Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia. |
| 25333665 | 2014 | Case report | AIDS | Successful treatment of HIV-associated severe aplastic anemia with eltrombopag; suggests an immunomodulatory effect (reduced Th1/Th17, increased Treg/Th ratio). |
| 28043314 | 2016 | Case report | Journal of the College of Physicians and Surgeons Pakistan | Case of hepatitis B (not HIV) leading to megaloblastic anemia and severe thrombocytopenia; tangential relevance. |
| 24128106 | 2013 | Case report | Farmacia Hospitalaria | Two case reports of eltrombopag for thrombocytopenia in chronic hepatitis C, not HIV. |
| 32977702 | 2020 | In vitro screening | Viruses | High-throughput screen of FDA-approved drugs identifying eltrombopag as a candidate modulator of HIV-1 proviral transcription — preclinical hypothesis only, not clinically validated. |
EU Market Information
Eltrombopag currently has no EU marketing authorization on record in this dataset (market status: Not Marketed, 0 authorizations). No product-level licensing data is available to tabulate.
Safety Considerations
Please refer to the SmPC for safety information.
(Key warnings, contraindications, and drug interaction data are marked as data gaps in the evidence pack — see DG001, a Blocking-severity gap that prevents a formal S1 safety assessment until TFDA/EMA label warnings are retrieved.)
Conclusion and Next Steps
Decision: Hold
Rationale: The clinical trial and literature evidence for this pairing almost entirely addresses eltrombopag’s established role in managing HIV-associated thrombocytopenia and aplastic anemia (a secondary complication), not a direct antiviral effect against HIV itself; the one mechanistic hypothesis for direct antiviral activity (PMID 32977702) is an unvalidated in vitro screening hit. Combined with a Blocking safety data gap and no EU marketing authorization, the evidence does not yet support proceeding.
To proceed, the following is needed:
- TFDA/EMA-sourced label warnings and contraindications (DG001, Blocking)
- A validated DrugBank/MOA record confirming mechanistic plausibility (DG002)
- Follow-up mechanistic or clinical work validating whether eltrombopag modulates HIV-1 proviral transcription in vivo, distinct from its known role in treating HIV-associated cytopenias
Note: Nine additional candidate indications were returned for this drug (ranks 2–10), but eight are scored “Hold” at evidence level L5 (model prediction only, including two veterinary/animal-model diseases and one obsolete disease term) or L4 with weak/indirect literature support (rheumatoid arthritis, female breast carcinoma). None currently warrant separate reporting beyond this top-ranked candidate.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.